Title (en)

aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES

Title (de)

APL-IMMUNREAKTIVE PEPTIDE, DEREN KONJUGATE UND VERFAHREN ZUR BEHANDLUNG VON APL-ANTIKÖRPERN VERMITTELTEN KRANKHEITEN

Title (fr)

PEPTIDES IMMUNOREACTIFS PAR RAPPORT AUX aPL, LEURS CONJUGUES ET PROCEDES DE TRAITEMENT DES PATHOLOGIES DEPENDANTES DE L'ANTICORPS aPL

Publication

EP 0954531 A4 19990831 (EN)

Application

EP 97933138 A 19970606

Priority

• US 9710075 W 19970606
• US 66009296 A 19960606
• US 76050896 A 19961205

Abstract (en)

[origin: WO9746251A1] aPL analogs that (a) bind specifially to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL antibody-mediated diseases. Conjugates comprising aPL analogs and nonimmunogenic valency platform molecules are provided as are novel nonimmunogenic valency platform molecules and linkers. Methods of preparing and identifying said analogs, methods of treatment using said analogs, methods and compositions for preparing conjugates of said analogs and diagnostic immunoassays for aPL antibodies are disclosed.

IPC 1-7

C07K 14/47; A61K 39/385; G01N 33/543; G01N 33/564; G01N 33/68; G01N 33/92

IPC 8 full level

A61K 31/00 (2006.01); A61K 38/00 (2006.01); A61K 38/03 (2006.01); A61K 39/00 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 25/00 (2006.01); A61P 37/00 (2006.01); A61P 37/06 (2006.01); C07K 7/06 (2006.01); C07K 14/47 (2006.01); C07K 16/44 (2006.01); C12Q 1/70 (2006.01); G01N 33/53 (2006.01); G01N 33/531 (2006.01); G01N 33/543 (2006.01); G01N 33/564 (2006.01); G01N 33/68 (2006.01); G01N 33/92 (2006.01)

CPC (source: EP KR)

A61K 38/03 (2013.01 - KR); A61K 39/0008 (2013.01 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/06 (2017.12 - EP); C07K 14/4713 (2013.01 - EP); G01N 33/54353 (2013.01 - EP); G01N 33/564 (2013.01 - EP); G01N 33/6878 (2013.01 - EP); G01N 33/92 (2013.01 - EP); A61K 38/00 (2013.01 - EP); A61K 2039/6093 (2013.01 - EP)

Citation (search report)

• [PX] WO 9640197 A1 19961219 - JOLLA PHARMA [US]
• [X] WO 9115722 A1 19911017 - MASUR WALTER [DE]
• [X] EP 0642798 A2 19950315 - JOLLA PHARMA [CA]
• [A] A.STEINKASSERER ET AL.: "Activity, disulphide mapping and structural modelling of the fifth domain of human beta2- glycoprotein", FEBS LETT., vol. 313, no. 2, 1992, pages 193 - 7, XP002111893
• [Y] S.A.LAUER ET AL.: "Amino acid sequence of the region beta2- glycoprotein 1 (gp1) which mediates binding of autoantibodies to the cardiolipin- gp1 complex in humans", IMMUNOLOGY, vol. 80, no. 1, 1993, pages 22 - 28, XP002111894
• [Y] J.HUNT ET AL.: "The fifth Domain of beta2- Glycoprotein I Contains a Phospholipid Binding site (Cys281- Cys288) and a Region Recognized by Anticardiolipin Antobodies", J.IMMUNOL., vol. 152, 1994, pages 563 - 9, XP002111895
• [Y] CWIRLA S E ET AL: "PEPTIDES ON PHAGE: A VAST LIBRARY OF PEPTIDES FOR IDENTIFYING LIGANDS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, August 1990 (1990-08-01), pages 6378 - 6382, XP002914848, ISSN: 0027-8424
• [Y] J.A.LESTRA ET AL.: "Isolation of sequences from a random-sequence expression library that mimics viral epitopes", J.IMMUNOL.METHODS, vol. 152, 1992, pages 149 - 57, XP002111896
• See references of WO 9746251A1

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9746251 A1 19971211; AU 3640497 A 19980105; AU 734638 B2 20010621; CA 2256449 A1 19971211; EP 0954531 A1 19991110; EP 0954531 A4 19990831; JP 2000512981 A 20001003; KR 20000016414 A 20000325; NO 985636 D0 19981203; NO 985636 L 19990208

DOCDB simple family (application)

US 9710075 W 19970606; AU 3640497 A 19970606; CA 2256449 A 19970606; EP 97933138 A 19970606; JP 50092798 A 19970606; KR 19980709997 A 19981207; NO 985636 A 19981203